CYP2D6 genotype and associated 5‐ HT 3 receptor antagonist outcomes: A systematic review and meta‐analysis
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70108 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Claire Moore und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapies, Stem Cell Medicine, Murdoch Children's Research Institute, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Serotonin 5-HT3 Receptor Antagonists, Postoperative Nausea and Vomiting. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
5‐hydroxytryptamine‐3 (5‐HT 3 ) receptor antagonists including ondansetron, tropisetron, dolasetron, palonosetron, granisetron, and ramosetron are commonly used to prevent and treat nausea and vomiting. Most of these medications are at least partially metabolized via the highly polymorphic CYP2D6 enzyme, resulting in variations of metabolism among individuals. Current (2017) international prescribing guidelines for ondansetron/tropisetron use according to genotype provide recommendations for CYP2D6 ultrarapid metabolizers but not intermediate or poor metabolizers. However, multiple studies have been conducted since this guideline was published. This review evaluated all available evidence of an association between CYP2D6 genotype and 5‐HT 3 receptor antagonist outcomes, including in patients who are CYP2D6 intermediate/poor metabolizers and pediatric‐specific studies. In this review, we confirm that CYP2D6 genotype impacts ondansetron response in a postoperative nausea and vomiting setting, which was supported by a meta‐analysis. We also highlight the heterogeneity and limitations of included studies as well as provide future directions for pharmacogenomics research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Therapies, Stem Cell Medicine, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
- Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
- Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
- The Novo Nordisk Foundation Centre for Stem Cell Medicine, ReNEW, Parkville, Victoria, Australia.
- Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia.
- Department of Aged Care and Medicine, The Royal Melbourne Hospital, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia.
ORCID-Profile: Claire Moore, Elizabeth Williams, Andreas Halman, Dhrita Khatri, Peter W Lange, Rachel Conyers
Zitieren
APA
Moore, C., Williams, E., Dyas, R., Halman, A., Stenta, T., Khatri, D., Elliott, D. A., Lange, P. W., Caudle, K. E., & Conyers, R. (2025). CYP2D6 genotype and associated 5‐ HT 3 receptor antagonist outcomes: A systematic review and meta‐analysis. Clinical and Translational Science. https://doi.org/10.1111/cts.70108
Vancouver
Moore C, Williams E, Dyas R, Halman A, Stenta T, Khatri D, et al. CYP2D6 genotype and associated 5‐ HT 3 receptor antagonist outcomes: A systematic review and meta‐analysis. Clinical and Translational Science. 2025. doi:10.1111/cts.70108
BibTeX
@article{Moore2025,
author = {Moore, Claire and Williams, Elizabeth and Dyas, Roxanne and Halman, Andreas and Stenta, Tayla and Khatri, Dhrita and Elliott, David A and Lange, Peter W and Caudle, Kelly E and Conyers, Rachel},
title = {CYP2D6 genotype and associated 5‐ HT 3 receptor antagonist outcomes: A systematic review and meta‐analysis},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70108}
}
EUVIMED